Skip to main content
ADGM
NASDAQ Life Sciences

Adagio Medical Launches Strategic Review, Cuts Workforce to Preserve Cash

Tom Rudovsky · Reported by BusinessWire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.489
Mkt Cap
$10.783M
52W Low
$0.363
52W High
$2.582
52W Position info
35% above low
Off High info
81% below high
Rel. Volume
Market data snapshot near publication time

ADGM sits 35% above its 52-week low of $0.363.

Summary

Adagio Medical's board has initiated a formal strategic alternatives process, including a possible sale or merger, and is cutting its workforce to align costs with prioritized programs. The company will reduce its workforce by 25 of 43 employees effective September 23, 2026, according to an SEC filing. Adagio disclosed a preliminary cash position of approximately $7.7 million as of June 30, 2026, which is modest relative to its development-stage operations. The strategic review and workforce reduction are material developments for a micro-cap company with a market cap around $10.8 million. Investors should watch for any announcements regarding potential acquirers or transaction terms, though the company has not set a timetable. Adagio lowered the conversion price of its 13% Senior Secured Convertible Notes to the Alternate Conversion Price for conversions from September 23 through October 31, 2026, subject to extension. The company estimates it will incur approximately $1.3 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs, excluding non-cash charges associated with equity-based compensation.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — Adagio lowered the conversion price of its 13% Senior Secured Convertible Notes to the Alternate Conversion Price for conversions from September 23 through October 31, 2026, subject to extension.

    • The Company estimates it will incur approximately $1.3 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based compensation).

At the time of this announcement, ADGM was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.36 to $2.58. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ADGM - Latest Insights

ADGM
Aug 13, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6901
Real-time Price: $0.149 info
Change: -$0.5411 (-78%) info
Market Cap: $3.309M info
ADGM
Aug 11, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7033
Real-time Price: $0.149 info
Change: -$0.5543 (-79%) info
Market Cap: $3.309M info
ADGM
Aug 11, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7033
Real-time Price: $0.149 info
Change: -$0.5543 (-79%) info
Market Cap: $3.309M info
ADGM
Jun 12, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.7999
Real-time Price: $0.149 info
Change: -$0.6509 (-81%) info
Market Cap: $3.309M info
ADGM
Jun 12, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7999
Real-time Price: $0.149 info
Change: -$0.6509 (-81%) info
Market Cap: $3.309M info